Sandoz division markets generic versions of the product, and its Alcon division markets Voltaren for ophthalmic indications. Ritalin, Ritalin LA, Focalin and Focalin XR (methylphenidate HCl, methylphenidate HCl extended release, dexmethylphenidate HCl and dexmethylphenidate HCl extended release) are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children. Ritalin LA and Focalin XR are additionally indicated for ADHD in adults. Ritalin is also indicated for narcolepsy. Ritalin is available in approximately 70 countries. Ritalin LA is available in 30 countries. Focalin comprises the active d-isomer of methylphenidate and therefore requires half the dose of Ritalin. Focalin and Focalin XR are available in the U.S. Cell and Gene Therapies In 2014, Novartis Pharmaceuticals created a franchise focused on the development and commercialization of Cell and Gene Therapies. The Cell and Gene Therapies franchise focuses on developing a new approach to treating or potentially curing patients suffering from various life-threatening diseases, including blood-borne cancers, sickle cell diseases, thalassemias, and other diseases of the blood by developing a portfolio of new treatments that replace, repopulate, and/or reprogram cells, and regulate the immune system. The franchise would initially focus on novel cell therapies and cell-based gene therapies, including Chimeric Antigen Receptor T-Cell technology in immuno-oncotherapy with CTL019, Facilitated Cell Therapy Platform (FCRx) in renal transplantation with FCR001, and stem cell expansion and transplantation with HSC835. Principal Markets The Pharmaceuticals division sells products in approximately 155 countries worldwide. Net sales are concentrated in the U.S., Europe, and Japan. The company sells its prescription drugs primarily to wholesale and retail drug distributors, hospitals, clinics, government agencies, and managed healthcare providers. Research and Development In 2015, the company’s Pharmaceuticals division research and development expenditure included $7.2 billion. Alcon division This division engages in the research, development, manufacturing, and marketing of eye care products worldwide. This division offers products serving the full lifecycle of patient needs across eye diseases, vision conditions, and refractive errors. To meet the needs of patients, ophthalmologists, surgeons, optometrists, opticians, and physician specialists, this division operates with three franchises, such as Surgical, Ophthalmic Pharmaceuticals, and Vision Care. This division’s products are available in approximately 180 markets. This division works together with the Novartis Institutes for BioMedical Research (NIBR), its global pharmaceutical research organization. This collaboration allows the company to leverage the resources of NIBR in an effort to discover and expand ophthalmic pharmaceutical research targets and to develop chemical and biologic compounds for the potential treatment of diseases of the eye, with a particular focus on diseases, such as glaucoma and macular degeneration. In July 2014, this division entered into an agreement with Verily to license its ‘smart lens’ technology with the potential to address ocular conditions. In October 2014, the company acquired WaveTec Vision Systems, Inc. The acquisition provides the company with the ORA System, the intra-operative guidance system for cataract surgeons implanting intraocular lenses (IOLs). Products Surgical This division’s surgical franchise offers ophthalmic surgical equipment, instruments, disposable products, and IOLs for surgical procedures that address cataracts, vitreoretinal conditions, glaucoma, and refractive errors. The company’s surgical portfolio comprises the Centurion vision system phacoemulsification technology platform; the LenSx laser, a femtosecond laser for increased precision and reproducibility for the corneal incision, capsulorhexis and lens fragmentation steps of the procedure; the Verion image guided system, an ocular surgical planning, imaging and guidance technology; the ORA System, an intra-operative guidance system fo
novartis ag-sponsored adr
(NVS:New York Consolidated)
Phone: 41 61 324 11 11
Fax: 41 61 324 80 01www.novartis.com
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for NVS.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact NOVARTIS AG-SPONSORED ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.